| Effect of platelet inhibition with cangrelor during PCI on ischemic events DL Bhatt, GW Stone, KW Mahaffey, CM Gibson, PG Steg, CW Hamm, ... New England Journal of Medicine 368 (14), 1303-1313, 2013 | 924 | 2013 |
| Bivalirudin started during emergency transport for primary PCI PG Steg, A Van't Hof, CW Hamm, P Clemmensen, F Lapostolle, P Coste, ... New England Journal of Medicine 369 (23), 2207-2217, 2013 | 593 | 2013 |
| Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial DJ Angiolillo, MS Firstenberg, MJ Price, PE Tummala, M Hutyra, IJ Welsby, ... Jama 307 (3), 265-274, 2012 | 568 | 2012 |
| American heart association council on E, prevention statistics c, stroke statistics s. heart disease and stroke statistics-2019 update: a report from the American heart association EJ Benjamin, P Muntner, A Alonso, MS Bittencourt, CW Callaway, ... Circulation 139 (10), e56-e528, 2019 | 512 | 2019 |
| Cardiovascular drug development: is it dead or just hibernating? CB Fordyce, MT Roe, T Ahmad, P Libby, JS Borer, WR Hiatt, MR Bristow, ... Journal of the American College of Cardiology 65 (15), 1567-1582, 2015 | 216 | 2015 |
| Maintenance of platelet inhibition during antiplatelet therapy LR Chen, S Skerjanec, D Bell, J Prats, M Todd US Patent 10,022,391, 2018 | 214 | 2018 |
| Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet … DJ Angiolillo, DJ Schneider, DL Bhatt, WJ French, MJ Price, JF Saucedo, ... Journal of thrombosis and thrombolysis 34, 44-55, 2012 | 174 | 2012 |
| Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to … BDL Généreux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ ... J Am Coll Cardiol 63 (7), 619-29, 2014 | 121 | 2014 |
| Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography) P Clemmensen, S Wiberg, A Van't Hof, EN Deliargyris, P Coste, ... JACC: Cardiovascular Interventions 8 (1 Part B), 214-220, 2015 | 100 | 2015 |
| Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in … GW Stone, T Clayton, EN Deliargyris, J Prats, R Mehran, SJ Pocock Journal of the American College of Cardiology 63 (1), 15-20, 2014 | 85 | 2014 |
| Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI G Giustino, R Mehran, GD Dangas, AJ Kirtane, B Redfors, P Généreux, ... Journal of the American College of Cardiology 70 (15), 1846-1857, 2017 | 77 | 2017 |
| Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous … GW Stone, P Genereux, RA Harrington, HD White, CM Gibson, PG Steg, ... European Heart Journal 39 (46), 4112-4121, 2018 | 56 | 2018 |
| Cangrelor with and without glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention M Vaduganathan, RA Harrington, GW Stone, EN Deliargyris, PG Steg, ... Journal of the American College of Cardiology 69 (2), 176-185, 2017 | 55 | 2017 |
| Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary … J Abtan, PG Steg, GW Stone, KW Mahaffey, CM Gibson, CW Hamm, ... JACC: Cardiovascular Interventions 9 (18), 1905-1913, 2016 | 55 | 2016 |
| Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice W Fan, S Plent, J Prats, EN Deliargyris The American journal of cardiology 117 (9), 1439-1443, 2016 | 54 | 2016 |
| Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: an exploratory … M Vaduganathan, RA Harrington, GW Stone, EN Deliargyris, PG Steg, ... JAMA cardiology 2 (2), 127-135, 2017 | 46 | 2017 |
| Consistent reduction in periprocedural myocardial infarction with cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX (Cangrelor Versus Standard … MA Cavender, DL Bhatt, GW Stone, HD White, PG Steg, CM Gibson, ... Circulation 134 (10), 723-733, 2016 | 43 | 2016 |
| Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard … PJ White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG ... JACC Cardiovasc Interv 8 (3), 424-33, 2015 | 43 | 2015 |
| Bivalirudin for the treatment of heparin-induced thrombocytopenia. PJ Bartholomew JR Heparin-Induced Thrombocytopenia, Ch 15 429-65, 2012 | 38 | 2012 |
| Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study DJ Angiolillo, DL Bhatt, F Lanza, B Cryer, J Dong, W Jeske, ... Journal of Thrombosis and Thrombolysis 48, 554-562, 2019 | 35 | 2019 |
